Timber Pharmaceuticals' candidate for rare skin disorder flunks all endpoints in late-stage trial

Katherine Lewin

News Reporter

Dermatology biotech Timber Pharmaceuticals’ Phase 3 trial investigating its treatment in a rare inherited skin disorder missed all primary and secondary endpoints, the company announced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Timber Pharmaceuticals' candidate for rare skin disorder flunks all endpoints in late-stage trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

J&J expands Tremfya into IBD with new FDA approval

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Tim­ber Phar­ma­ceu­ti­cal­s' can­di­date for rare skin dis­or­der flunks all end­points in late-stage tri­al

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Timber Pharmaceuticals' candidate for rare skin disorder flunks all endpoints in late-stage trial